| Added by | Cavailles |
|---|---|
| Group name | EquipeVC |
| Item Type | Journal Article |
| Title | Pharmacist intervention to detect drug adverse events on admission to the emergency department: Two case reports of neuroleptic malignant syndrome |
| Creator | Leenhardt et al. |
| Author | F. Leenhardt |
| Author | D. Perier |
| Author | V. Pinzani |
| Author | I. Giraud |
| Author | M. Villiet |
| Author | A. Castet-Nicolas |
| Author | V. Gourhant |
| Author | C. Breuker |
| Abstract | WHAT IS KNOWN AND OBJECTIVE: Neuroleptic malignant syndrome (NMS) is a rare but severe adverse effect of antipsychotic drugs. CASE DESCRIPTION: We report two cases of NMS highlighted by clinical pharmacists in an emergency unit during summer. One of them was fatal. Medication reconciliation processes performed at admission identified treatment with loxapine for one of them and with loxapine and clozapine for the other. Interview of the patients highlighted clinical symptoms suggesting NMS, allowing the pharmacists to alert the medical team. WHAT IS NEW AND CONCLUSION: Adverse drug events may be severe and clinical pharmacists in emergency departments can help to detect them. |
| Publication | Journal of Clinical Pharmacy and Therapeutics |
| Volume | 42 |
| Issue | 4 |
| Pages | 502-505 |
| Date | Aug 2017 |
| Journal Abbr | J Clin Pharm Ther |
| Language | eng |
| DOI | 10.1111/jcpt.12531 |
| ISSN | 1365-2710 |
| Short Title | Pharmacist intervention to detect drug adverse events on admission to the emergency department |
| Library Catalog | PubMed |
| Extra | PMID: 28488314 |
| Tags | accident and emergency departments, adverse effect, Aged, Antipsychotic Agents, clinic, clinical pharmacy, Clozapine, Emergency Service, Hospital, Fatal Outcome, Humans, Loxapine, Male, Middle Aged, Neuroleptic Malignant Syndrome, pharmacist consultation, Pharmacists, Pharmacy Service, Hospital, Professional Role |
| Date Added | 2019/05/16 - 15:32:54 |
| Date Modified | 2019/05/16 - 15:57:31 |
| Notes and Attachments | PubMed entry (Attachment) |
Institut de Recherche en Cancérologie de
